Month: February 2026

• UBT251 是一款 GLP-1/GIP /GCG三靶点受体激动剂（三激动剂），由联邦生物与诺和诺德联合开发
• 在一项针对中国超重或肥胖患者的安慰剂对照 II 期临床研究中，用药 24 周后受试者平均体重降幅高达 19.7%，具有统计学意义
• UBT251 的安全性和耐受性良好，与基于肠促胰素的疗法一致

中国广东和丹麦巴格斯韦德 – Media OutReach Newswire – 2026年2月24日 – 联邦制药国际控股有限公司（「联邦制药」）与Novo Nordisk A/S（「诺和诺德」）今日宣布GLP-1/GIP/GCG三靶点受体激动剂（三激动剂）UBT251中国II期临床研究的主要结果。

UBT251 由联邦制药之全资附属公司——联邦生物科技（珠海横琴）有限公司（「联邦生物」）与诺和诺德根据 2025 年 3 月签署许可协议共同开发。联邦生物负责中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区的开发，诺和诺德负责除上述外全球范围内的开发。

本次临床研究由联邦生物开展，旨在研究中国超重或肥胖患者每周一次注射2 mg、4 mg和6 mg剂量的UBT251与安慰剂对照的安全性和有效性。患者基线平均体重为92.2 kg，治疗24周后，UBT251治疗组的平均体重降幅最高达19.7%（-17.5 kg），而安慰剂组仅为2.0%（-1.6 kg）¹。

此外，与安慰剂组相比，UBT251 所有剂量组在关键次要终点方面均显示出统计学显著改善，包括腰围、血糖、血压和血脂。

本次研究中，UBT251 显示出良好的安全性和耐受性。最常见的不良事件为胃肠道反应，绝大多数为轻度至中度，且随时间推移而减轻，这与基于肠促胰素的疗法一致。

「UBT251中国II期临床研究的成功，是联邦制药创新发展的又一重要里程碑。」联邦制药主席蔡海山先生表示，「我们将持续聚焦内分泌和代谢性疾病等慢性疾病治疗领域，加速推进UBT251的后续开发，早日为全球患者提供更多优质治疗选择。」

「中国临床研究取得的结果令我们倍感鼓舞，展现了UBT251的潜力及其差异化的临床特征、安全性和耐受性特征，」诺和诺德执行副总裁、首席科学官兼研发负责人Martin Holst Lange表示，「我们期待明年公布诺和诺德开展的UBT251全球研究数据。」

诺和诺德近期启动了一项全球性Ib/IIa 期临床研究，旨在研究不同剂量 UBT251 在约 330 名超重或肥胖患者中长达 28 周的安全性、耐受性、药代动力学和药效学。该研究的主要数据预计将于 2027 年公布。诺和诺德还计划于 2026 年下半年启动一项针对 2 型糖尿病患者的UBT251的 II期临床研究。

联邦生物将于今年晚些时候在医学大会期间公布其中国II期临床研究的详细数据。基于该研究结果，联邦制药计划启动一项针对中国超重或肥胖患者的III期临床研究。

关于中国II期临床研究

这项随机、双盲、安慰剂对照研究共纳入205名中国肥胖（BMI≥28.0 kg/m²）或超重（24.0 kg/m²≤BMI<28.0 kg/m²）且至少合并一种体重相关疾病的患者。患者基线平均体重为92.2 kg，基线平均BMI为33.1 kg/m²。

患者被随机分配接受每周一次皮下注射2 mg、4 mg、6 mg剂量的 UBT251或安慰剂，疗程为 24 周。

该研究的主要终点是治疗 24 周后体重较基线的百分比变化。

关于UBT251

UBT251是一种长效合成肽类GLP-1（胰高血糖素样肽-1）、GIP（葡萄糖依赖性促胰岛素多肽）和GCG（胰高血糖素）三靶点受体激动剂。

2025年3月，联邦生物与诺和诺德就UBT251达成独家许可协议。根据该协议，诺和诺德获得UBT251在全球范围内（除中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区）的独家开发、生产和商业化权利。联邦生物保留UBT251在中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区的相关权利。

______________________________
¹ 根据试验方案的疗效估计值，不考虑剂量调整

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

关于联邦制药和联邦生物

联邦制药（香港联交所股票代码：3933）创立于一九九零年，主要从事药品的研发、生产及销售，是中国领先的综合性制药企业之一。目前拥有七家生产基地，产品涵盖医药中间体及原料药、制剂产品、兽药、药用空心胶囊、医疗器械，销售网络覆盖全球近80个国家和地区。联邦生物位于横琴粤澳深度合作区，是联邦制药的生物医药研发总部，主要研发治疗重大慢性疾病的高端生物药物。更多信息，请访问www.tul.com.cn。

关于诺和诺德

诺和诺德是一家全球领先的医疗健康公司，成立于1923年，总部位于丹麦。我们的使命是基于在糖尿病领域的深厚积淀，推动变革以战胜严重慢性疾病。我们通过开创科学突破、扩大药物可及性以及致力于预防并最终治愈疾病来实现这一目标。诺和诺德在80个国家拥有约68,800名员工，产品销往约170个国家。更多信息，请访问novonordisk.com,Facebook, Instagram, X, LinkedIn和YouTube。

• UBT251 是一款 GLP-1/GIP /GCG三靶點受體激動劑（三激動劑），由聯邦生物與諾和諾德聯合開發
• 在一項針對中國超重或肥胖患者的安慰劑對照 II 期臨床研究中，用藥 24 周後受試者平均體重降幅高達 19.7%，具有統計學意義
• UBT251 的安全性和耐受性良好，與基於腸促胰素的療法一致

中國廣東和丹麥巴格斯韋德 – Media OutReach Newswire – 2026年2月24日 – 聯邦制藥國際控股有限公司（「聯邦制藥」）與Novo Nordisk A/S（「諾和諾德」）今日宣佈GLP-1/GIP/GCG三靶點受體激動劑（三激動劑）UBT251中國II期臨床研究的主要結果。

UBT251 由聯邦制藥之全資附屬公司——聯邦生物科技（珠海橫琴）有限公司（「聯邦生物」）與諾和諾德根據 2025 年 3 月簽署許可協議共同開發。聯邦生物負責中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區的開發，諾和諾德負責除上述外全球範圍內的開發。

本次臨床研究由聯邦生物開展，旨在研究中國超重或肥胖患者每週一次注射2 mg、4 mg和6 mg劑量的UBT251與安慰劑對照的安全性和有效性。患者基線平均體重為92.2 kg，治療24周後，UBT251治療組的平均體重降幅最高達19.7%（-17.5 kg），而安慰劑組僅為2.0%（-1.6 kg）¹。

此外，與安慰劑組相比，UBT251 所有劑量組在關鍵次要終點方面均顯示出統計學顯著改善，包括腰圍、血糖、血壓和血脂。

本次研究中，UBT251 顯示出良好的安全性和耐受性。最常見的不良事件為胃腸道反應，絕大多數為輕度至中度，且隨時間推移而減輕，這與基於腸促胰素的療法一致。

「UBT251中國II期臨床研究的成功，是聯邦制藥創新發展的又一重要里程碑。」聯邦制藥主席蔡海山先生表示，「我們將持續聚焦內分泌和代謝性疾病等慢性疾病治療領域，加速推進UBT251的後續開發，早日為全球患者提供更多優質治療選擇。」

「中國臨床研究取得的結果令我們倍感鼓舞，展現了UBT251的潛力及其差異化的臨床特徵、安全性和耐受性特徵，」諾和諾德執行副總裁、首席科學官兼研發負責人Martin Holst Lange表示，「我們期待明年公佈諾和諾德開展的UBT251全球研究數據。」

諾和諾德近期啟動了一項全球性Ib/IIa 期臨床研究，旨在研究不同劑量 UBT251 在約 330 名超重或肥胖患者中長達 28 周的安全性、耐受性、藥代動力學和藥效學。該研究的主要數據預計將於 2027 年公佈。諾和諾德還計劃於 2026 年下半年啟動一項針對 2 型糖尿病患者的UBT251的 II期臨床研究。

聯邦生物將於今年晚些時候在醫學大會期間公佈其中國II期臨床研究的詳細數據。基於該研究結果，聯邦制藥計劃啟動一項針對中國超重或肥胖患者的III期臨床研究。

關於中國II期臨床研究

這項隨機、雙盲、安慰劑對照研究共納入205名中國肥胖（BMI≥28.0 kg/m²）或超重（24.0 kg/m²≤BMI<28.0 kg/m²）且至少合併一種體重相關疾病的患者。患者基線平均體重為92.2 kg，基線平均BMI為33.1 kg/m²。

患者被隨機分配接受每週一次皮下注射 2 mg、4 mg、6 mg劑量的UBT251或安慰劑，療程為 24 周。

該研究的主要終點是治療 24 周後體重較基線的百分比變化。

關於UBT251

UBT251是一種長效合成肽類GLP-1（胰高血糖素樣肽-1）、GIP（葡萄糖依賴性促胰島素多肽）和GCG（胰高血糖素）三靶點受體激動劑。

2025年3月，聯邦生物與諾和諾德就UBT251達成獨家許可協議。根據該協議，諾和諾德獲得UBT251在全球範圍內（除中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區）的獨家開發、生產和商業化權利。聯邦生物保留UBT251在中國內地（大陸）、香港特別行政區、澳門特別行政區和臺灣地區的相關權利。

______________________________
¹ 根據試驗方案的療效估計值，不考慮劑量調整

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

關於聯邦制藥和聯邦生物

聯邦制藥（香港聯交所股票代碼：3933）創立於一九九零年，主要從事藥品的研發、生產及銷售，是中國領先的綜合性製藥企業之一。目前擁有七家生產基地，產品涵蓋醫藥中間體及原料藥、製劑產品、獸藥、藥用空心膠囊、醫療器械，銷售網絡覆蓋全球近80個國家和地區。聯邦生物位於橫琴粵澳深度合作區，是聯邦制藥的生物醫藥研發總部，主要研發治療重大慢性疾病的高端生物藥物。更多資訊，請訪問www.tul.com.cn。

關於諾和諾德

諾和諾德是一家全球領先的醫療健康公司，成立於1923年，總部位於丹麥。我們的使命是基於在糖尿病領域的深厚積澱，推動變革以戰勝嚴重慢性疾病。我們通過開創科學突破、擴大藥物可及性以及致力於預防並最終治癒疾病來實現這一目標。諾和諾德在80個國家擁有約68,800名員工，產品銷往約170個國家。更多資訊，請訪問novonordisk.com,Facebook, Instagram, X, LinkedIn和YouTube。

• UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
• In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
• UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.

GUANGDONG, CHINA & BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 February 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).

UBT251 is being jointly developed by TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology) and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.

The trial, conducted by United Biotechnology, investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo in Chinese people with overweight or obesity. From a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7% (-17.5 kg) compared to 2.0% (-1.6kg) in the placebo group after 24 weeks of treatment[i].

Moreover, all dose groups of UBT251 showed statistically significant improvements relative to placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure and lipids.

In the trial, UBT251 appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with incretin-based therapies.

“The success of the phase 2 clinical trial of UBT251 in China represents another significant milestone in TUL’s innovation-driven development,” said Mr Tsoi Hoi Shan, Chairman of TUL. “We will continue to focus on chronic diseases, including endocrine and metabolic disorders, accelerate the further development of UBT251, and strive to bring more high-quality treatment options to patients worldwide at the earliest opportunity.”

“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”

Novo Nordisk recently initiated a global phase 1b/2a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of UBT251 for up to 28 weeks in around 330 people living with overweight or obesity. Topline data from that trial is expected in 2027. Novo Nordisk also expects to initiate a phase 2 trial with UBT251 in people with type 2 diabetes in the second half of 2026.

United Biotechnology will present detailed data from the Chinese phase 2 trial at a medical congress later this year. Based on the results of this trial, the company is planning to initiate a phase 3 trial in Chinese patients with overweight or obesity.

About the Chinese phase 2 trial

This randomized, double-blind, placebo-controlled trial enrolled a total of 205 Chinese patients with obesity (BMI ≥ 28.0 kg/m²) or overweight (24.0 kg/m² ≤ BMI < 28.0 kg/m²) with at least one weight-related comorbidity. The baseline mean body weight of the patients was 92.2 kg, with a baseline mean BMI of 33.1 kg/m².

Patients were randomly assigned to receive weekly subcutaneous injections of UBT251 in doses of 2 mg, 4 mg, 6 mg, or placebo for 24 weeks.

The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

In March 2025, United Biotechnology entered an exclusive license agreement with Novo Nordisk A/S for UBT251. Under the agreement, Novo Nordisk obtained exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialise UBT251. United Biotechnology retained the rights for UBT251 in Chinese mainland, Hong Kong, Macau and Taiwan.

Hashtag: #UBT251

The issuer is solely responsible for the content of this announcement.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine, finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit www.tul.com.cn.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Debut at startup-centric zone 4YFN, Dual-presence at World Class Tech Exhibitions in Spain

HONG KONG SAR – Media OutReach Newswire – 24 February 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with Hong Kong Trade Development Council (HKTDC), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain.

Building on the momentum from MWC 2025—the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.

Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”

Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”

A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:

• 5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.

• Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.

HKSTP continues to join hands with HKTDC to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.

Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)
Date: 2-5 March 2026
Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L’Hospitalet de Llobregat, Barcelona, Spain

Hong Kong Tech Pavilion:
MWC – Booth 6E44 at Hall 6
4YFN – Booth 8.1B31 at Hall 8.1

Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.

Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)

Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

HKSTP

More information about HKSTP is available at www.hkstp.org

This year’s edition sees six coffee shops from the region secure placements in the Top 100 List

SINGAPORE – Media OutReach Newswire – 23 February 2026 – The second edition of THE WORLD’S 100 BEST COFFEE SHOPS 2026 with DaVinci Gourmet announced its global ranking at CoffeeFest Madrid 2026 on 16 February 2026. This year marks a breakthrough moment for the Middle East. The United Arab Emirates secured two placements in the global Top 100, reinforcing its position as a fast-growing specialty coffee hub. In addition, Qatar and Oman achieved their first-ever entries in the global ranking, and Turkey’s Meet Lab Coffee returned to the list, underscoring the region’s growing presence on the world coffee stage.

The list confirms the emergence of new global capitals of quality coffee, as well as the consolidation of an increasingly diverse and innovative international coffee community that includes The United States, which leads the ranking with nine selected coffee shops, South America, Europe, Asia Pacific, Africa and Middle East.

Middle East coffee shops that made the Top 100 Ranking:

• Benchmark Coffee, UAE

• Harvest Coffee, Qatar

• Meet Lab Coffee, Turkey

• Azura – The Coffee Company, Oman

• Cypher Urban Roastery, UAE

• Flat White Specialty Coffee, Qatar

Hashtag: #TheWorlds100BestCoffeeShop #DaVinciGourmet

The issuer is solely responsible for the content of this announcement.

The partnership is designed to provide greater confidence throughout the EV ownership journey—ensuring that premium electric vehicles are supported by reliable charging solutions, responsive roadside assistance, and integrated digital services. By combining VinFast’s expanding EV presence in the UAE with PlusX Electric’s on-demand charging capabilities and infrastructure expertise, the two parties will work together to deliver a seamless, convenience-led, and assurance-driven experience for VinFast drivers.

Under the MoU, VinFast and PlusX Electric will collaborate across a structured set of initiatives focused on charging availability, ownership support, and infrastructure enablement across key use cases, including home, workplace, fleet, and on-road assistance.

Specifically, the two parties aim to deploy Portable EV Charging Pods to meet customers’ flexible charging needs during vehicle usage, while enabling access to On-Demand Mobile Charging services designed to assist in time-sensitive situations. The partnership will also explore EV Roadside Assistance (RSA) – Emergency Charging services, helping reduce range anxiety and vehicle downtime while strengthening customer assurance through clearly defined service workflows and operational readiness.

In addition, PlusX Electric may become a preferred partner for the supply, installation, and aftersales support of Home & Office Chargers for VinFast customers in the UAE, in alignment with applicable UAE compliance requirements. For commercial and fleet segments, the two parties will explore scalable solutions such as DC Fast Charger Leasing and dedicated mobile charging support, ensuring operational continuity and efficiency for B2B and fleet customers.

As part of the collaboration, VinFast and PlusX Electric will further explore digital integration initiatives to streamline how customers access charging services, manage bookings, and receive service updates through partner platforms. The two parties will also assess potential integration of EV insurance offerings via the PlusX App and explore co-branding opportunities, including VinFast branding on PlusX Power Pods, with the objective of delivering a cohesive and fully integrated EV ecosystem experience.

Ms. Do Hoai Linh, CEO of VinFast Middle East, shared: “VinFast is committed to building a long-term and comprehensive EV ecosystem in the UAE—one that gives customers confidence not only in the quality and performance of our electric vehicles, but also in the reliability and accessibility of the supporting infrastructure. Through this MoU with PlusX Electric, we are strengthening the support layer around EV adoption by expanding access to flexible charging solutions, emergency assistance services, and integrated digital touchpoints. By working with a DEWA-approved partner that understands local regulatory requirements and operational realities, we aim to make EV ownership simpler, more dependable, and better aligned with the expectations of customers in the Middle East.”

Chintan Sareen – Founder and CEO of PlusX Electric added: “EV adoption accelerates when customers trust that charging and support are always within reach. Our collaboration with VinFast reflects a shared commitment to strengthening the EV ownership ecosystem in the UAE through dependable infrastructure, responsive roadside services, and customer-centric digital solutions. As a DEWA-approved provider, PlusX Electric brings localized expertise in charger supply and installation, mobile charging operations, and fleet enablement. Together with VinFast, we look forward to delivering practical, scalable solutions that enhance service reliability, reduce range anxiety, and support the continued growth of sustainable mobility in the region.”

Across the Middle East, VinFast continues to expand its presence through strategic partnerships, strengthened aftersales capabilities, and the development of EV-supporting infrastructure. The collaboration with PlusX Electric underscores VinFast’s long-term commitment to supporting customers throughout their ownership journey and contributing to the UAE’s transition toward sustainable and future-ready mobility solutions.

Hashtag: #Vinfast

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC — one of Vietnam’s largest private conglomerates — is a pure electric vehicle (EV) manufacturer with a mission to make EVs more accessible to all. Its current product lineup includes a range of electric SUVs, e-scooters, e-bikes, and electric buses.

VinFast is entering its next phase of global growth by rapidly expanding its distribution and dealership network, strengthening manufacturing capabilities, and focusing on key markets in North America, Europe, and Asia.

Learn more about VinFast: https://me.vinfast.com/en

About PlusX Electric

PlusX Electric is a DEWA-approved EV charging and electric mobility solutions company in the UAE, offering end-to-end charging services including charger supply and installation, mobile charging solutions, EV roadside assistance, and fleet charging partnerships. PlusX Electric is committed to making EV charging more accessible, reliable, and convenient for both individual and commercial customers across the UAE.

汇聚全球学术领袖 领航打造亚太太空枢纽

香港 – Media OutReach Newswire – 2026年2月23日 – 被誉为「天文界奥林匹克」的亚太区天文学大会（APRIM）将于2026年5月4日至8日首次在香港举行，会议地点为香港会议展览中心。大会由国际天文学联合会（IAU）主办、香港大学太空研究实验室（LSR）承办，届时世界各地的天文学者与科研人员云集香江，交流最新研究成果。作为亚太区最具影响力的天文学术权威会议，APRIM今次选址香港，不仅印证了国际学术界对本港科研实力的认同，更标誌着香港正式领航亚太天文科研发展，有利本港深化STEM教育、推动跨界科研合作，是构建香港作为亚太区太空枢纽的关键里程碑。

香港打造亚太太空枢纽 科研实力获国际认可
亚太区天文学大会主席及香港大学太空研究实验室总监柏坤霆教授（Prof. Quentin Parker）表示，能够将这场「天文界奥林匹克」首次 带到香港，既是对本港科研实力的肯定，也为本地青年与产业创造与国际专家直接对话的机会。

前中国科学院国家天文台副台长薛随建教授分析，香港获国际天文学联合会选定为主办城市，关键在于本港高度国际化的环境及稳健的经济基础。他指出，香港在深空探测、行星科学及大数据分析等范畴表现突出，加上长期担当国际科研交流的桥樑，正是联合会决定在港举办会议的原因。

从「旧太空」迈向「新太空」连结基础研究与未来可能
APRIM2026不仅是一个学术交流平台，更是连接基础科学与实际应用的桥樑。随着全球航天产业由政府主导转向商业化与普及化的「新太空」时代，大会将探讨如何将前沿的天体物理学理论，转化为造福人类的实际应用。

大会预计将汇聚近千名专家，议题横跨行星科学、恒星演化及宇宙学等核心领域。除了探讨宇宙起源等议题，亦将聚焦行星科学、恒星演化与宇宙学等，探讨这些前沿技术如何为应对全球挑战。

倡导「太空可持续发展」为大会焦点
APRIM2026将以香港为主场，汇聚亚太及全球天文学界代表，议题涵盖行星科学、恒星演化、星系动力学、宇宙学及观测天文学等多元议题；面对日益拥挤的近地轨道（LEO），「太空可持续发展」（Space Sustainability）成为本届大会的焦点议题。与会科学家将深入探讨空间碎片（Space Debris）治理、⁠光污染及 地基观测影响、卫星 频谱与 信号干扰、轨道拥堵管理与政策协调扰等议题。

透过一系列专题研讨及公众工作坊，大会致力于在学术界及公众之间建立对话，倡导负责任的太空探索精神，确保人类能永续地利用外太空资源，更期望能启迪年轻一代对宇宙探索的志趣，为香港未来的创科发展培育更多生力军。

北京大学科维理天文与天体物理研究所所长何子山教授（Prof. Luis C. Ho）形容大会为凝聚亚太科研力量的重要平台，向世界展示亚洲太空科研实力，从基础研究迈向产业应用，开拓太空新潜力。

The issuer is solely responsible for the content of this announcement.

关于各机构

国际天文学联合会
国际天文学联合会（IAU）汇聚来自 85 个国家的超过 13,000 名专业天文学家。其使命是透过国际合作，促进及保障天文学科学的各方面发展。欲了解更多资讯，请参看以下连结：https://iau.org

香港大学太空研究实验室
香港大学太空研究实验室（LSR）是香港大学的一个跨学科中心，致力于透过卫星研究及学术合作，推进太空科学、行星研究及高能天体物理学。欲了解更多资讯，请参看以下网址：https://www.lsr.hku.hk

鑽石贊助
邵逸夫奖

金贊助
中国科学院空间应用工程与技术中心

铜贊助
香港（国际）航天慈善基金会

主办机构
香港大学 太空研究实验室
国际天文学联合会

大会公关
MEMO PLUS PR & CONSULTANTS

支持机构
飞龙太空科技有限公司
创星汇
香港旅游发展局
中国科学院紫金山天文台
香港大学
北京大学科维理天文与天体物理研究所
印度卫星通信业协会
中国科学院国家天文台
国际射电天文学研究中心
西澳大学 国际太空中心
* 香港桂冠论坛
团结香港基金
自然科学研究机构
日本国立天文台
中国科学院香港创新研究院
中央研究院天文及天文物理研究所
Three Country Trusted Broker
联合国外层空间事务厅

Swiss technology company SICPA secured a landmark traceability contract, in partnership with Spectra Systems Corporation’s subsidiary, Cartor Security Printers (Cartor), reinforcing its global leadership in secure track and trace (T&T) technology. The program will deliver robust traceability solutions to His Majesty’s Revenue and Customs (HMRC) for vape products in the United Kingdom.

PRILLY, SWITZERLAND – EQS Newswire – 23 February 2026 – Building on SICPA’s proven experience in deploying secure T&T systems for excisable products and leveraging Cartor’s advanced security printing capabilities, the consortium will deliver a robust solution combining banknote-grade security features with state-of-the-art digital systems to effectively combat the illicit trade of vape products.

The solution will enable HMRC to support excise duty collection, enhance market compliance, protect consumers, and further strengthen its fight against illicit trade.
Following a multistage procurement process launched by HMRC in July 2025, the consortium was appointed upon detailed assessment of technical and financial submissions. The project will run for an initial five-year term, with an option for a further one-year extension. The system will be implemented in phases, beginning with a transitional duty stamp from April 2026, followed by an enhanced stamp supported by a full track and trace solution from October 2026.

Cartor will be responsible for the printing of tax stamps with the provision of core security features. SICPA will complement these with additional material and digital security features that further reinforce the system’s robustness, while also managing tax stamp coding and the track and trace software solutions. Its role also includes managing stakeholder and product registration, tax stamp ordering and payments processes, as well as data collection and compliance monitoring for HMRC across the vape products supply chain. SICPA’s advanced digital market intelligence capabilities will further enable the identification of suspicious patterns and potential fraud hotspots, while audit devices for enforcement authorities and consumer verification applications will support in tackling fraud and fakes.

“We are glad to support His Majesty’s Revenue and Customs in its mission to secure the market against illicit trade, building on decades of experience in excisable products secure traceability systems and the successes of our program throughout the world,” said Philippe Amon, Chairman and CEO of SICPA.

“Cartor is proud to work alongside SICPA to deliver this important program for HMRC,” said Andrew Brigham, Cartor’s Managing Director. “By combining our complementary strengths, this partnership delivers a trusted solution for our customer and the UK vapes market, while supporting the UK’s efforts to protect both public revenues and consumers.”

Hashtag: #SICPA

The issuer is solely responsible for the content of this announcement.

About SICPA

Established in 1927, SICPA is a Swiss private technology company that supports the effective governance and long-term prosperity of nations.
SICPA sets the pulse of sovereignty, enabling governments to protect their citizens, sovereign assets, and economies. Best known for securing the majority of the world’s banknotes, SICPA operates across five continents. Today, our platform for sovereignty delivers integrated solutions safeguarding revenue mobilisation, natural resources, health, and brand protection as well as digital sovereignty and secure public services. www.sicpa.com

About Spectra Systems Corporation

Spectra Systems is a global provider of advanced authentication, brand protection, and secure transaction technologies. Cartor Security Printers is a part of Spectra Systems and a leading European security printing and brand protection specialist, supporting governments and brand owners with high-security solutions designed to protect revenues and combat illicit trade. Together, they deliver proven overt and covert security features for excise applications, tax stamps and regulated markets worldwide. www.spsy.com, www.cartor.com

Địa điểm mới mở rộng cơ sở hạ tầng toàn cầu của công ty, đồng thời cung cấp khả năng xử lý dữ liệu nhanh hơn, các biện pháp bảo mật ưu trội và năng lực tuân thủ các quy định pháp lý tốt hơn.

SINGAPORE – Media OutReach Newswire – Ngày 23 tháng 2 năm 2026- Anaplan, công ty dẫn đầu toàn cầu về lập kế hoạch và phân tích kịch bản dựa trên trí tuệ nhân tạo (AI), hôm nay đã công bố việc ra mắt trung tâm dữ liệu Amazon Web Services mới tại Singapore. Hoạt động mở rộng chiến lược này hướng đến mục tiêu đẩy nhanh quá trình chuyển đổi số và hỗ trợ doanh nghiệp tại khu vực Đông Nam Á khai thác các năng lực của trí tuệ nhân tạo tiên tiến, từ đó lập kế hoạch và ra quyết định trong thời gian thực.

Trung tâm dữ liệu mới sẽ tăng cường đáng kể cơ sở hạ tầng toàn cầu của Anaplan, đồng thời cung cấp khả năng xử lý dữ liệu nhanh hơn, nâng cao bảo mật và khả năng tuân thủ các quy định pháp lý tốt hơn. Những tính năng này đóng vai trò thiết yếu trong việc bảo vệ thông tin nhạy cảm và đáp ứng các yêu cầu về chủ quyền dữ liệu địa phương, đây là điều đặc biệt quan trọng đối với các ngành như khu vực công và dịch vụ tài chính.

Bà Carol Potts, Tổng Giám đốc phụ trách bán hàng cho Nhà cung cấp mềm độc lập (ISV) khu vực Bắc Mỹ tại AWS, cho biết: “Triển khai hoạt động của Anaplan trên nền tảng AWS tại Singapore đánh dấu một cột mốc chiến lược và củng cố cam kết chung của chúng tôi đối với khách hàng trên khắp khu vực châu Á – Thái Bình Dương”.

Bằng cách tận dụng nền tảng Anaplan, các doanh nghiệp trong khu vực sẽ có quyền truy cập vào các công nghệ AI và máy học hàng đầu, cho phép họ:

• Tối ưu hóa quy trình lập kế hoạch: Thông tin chi tiết do AI cung cấp sẽ giúp doanh nghiệp đưa ra các quyết định sáng suốt hơn, dựa trên dữ liệu trong thời gian thực, giúp tinh giản hoạt động và nâng cao hiệu quả.
• Tăng cường bảo mật dữ liệu: Trung tâm dữ liệu đảm bảo dữ liệu được lưu trữ tại Singapore và tuân thủ các quy định pháp lý tại địa phương.
• Thúc đẩy đổi mới dựa trên AI: Được hỗ trợ bởi cơ sở hạ tầng đáng tin cậy và an toàn, các công ty có thể mở rộng quy mô hoạt động bằng cách tích hợp công nghệ AI tiên tiến trực tiếp vào các quy trình và luồng công việc lập kế hoạch liên phòng ban, giúp đội ngũ nhân sự hoạt động nhanh hơn, đưa ra quyết định thông minh hơn và duy trì lợi thế cạnh tranh.

Ông Amit Bagga, Giám đốc điều hành khu vực Châu Á Thái Bình Dương của Anaplan, cho biết: “Chúng tôi rất vui mừng khi mang nền tảng Anaplan, bao gồm cả bộ công cụ AI dựa trên vai trò mới của chúng tôi, đến Singapore và rộng hơn là khu vực Đông Nam Á. Chủ quyền dữ liệu là một yêu cầu nghiêm ngặt đối với khách hàng của chúng tôi, và địa điểm mới này đảm bảo rằng dữ liệu của họ được lưu trữ trong phạm vi Singapore, tuân thủ các quy định địa phương. Hơn nữa, với Anaplan Intelligence, các doanh nghiệp có thể khai thác sức mạnh của AI để tối ưu hóa và hợp nhất các quy trình lập kế hoạch tài chính, nhân lực, bán hàng và chuỗi cung ứng, thu được những thông tin chuyên sâu hơn và tự tin đưa ra các quyết định chiến lược”.

Hoạt động mở rộng phạm vi khu vực này đánh dấu một cột mốc quan trọng khác trong lộ trình đổi mới trị giá 500 triệu đô la của Anaplan, nhằm mục đích mở rộng phạm vi hoạt động toàn cầu của công ty và hỗ trợ các doanh nghiệp địa phương bằng công nghệ lập kế hoạch và phân tích dựa trên AI mới nhất. Công ty cũng đã mở rộng thêm các trung tâm dữ liệu khác trong khu vực châu Á – Thái Bình Dương, bao gồm Ấn Độ, Indonesia, và Úc, củng cố hơn nữa cam kết của công ty đối với khu vực này.

Hashtag: #Anaplan

The issuer is solely responsible for the content of this announcement.

Giới thiệu về Anaplan

Anaplan là nền tảng lập kế hoạch và phân tích kịch bản dựa trên AI duy nhất được thiết kế nhằm tối ưu hóa việc đưa ra quyết định trong môi trường kinh doanh phức tạp hiện nay, giúp các doanh nghiệp vượt trội hơn đối thủ cạnh tranh và thị trường. Bằng cách xây dựng các kết nối và sự hợp tác giữa các bộ phận trong tổ chức, nền tảng của chúng tôi cung cấp thông tin chuyên sâu quan trọng một cách thông minh — để các doanh nghiệp có thể đưa ra quyết định đúng đắn ngay tại thời điểm cần thiết. Hơn 2.500 thương hiệu hàng đầu thế giới, bao gồm gần một nửa trong số các công ty thuộc Fortune 50, liên tục tối ưu hóa hoạt động ra quyết định thông qua việc lập kế hoạch với Anaplan. Để tìm hiểu thêm, vui lòng truy cập www.anaplan.com.